LANGLEY PORTER PSYCHIATRIC HOSPITAL
- Type
- Teaching hospital
- Where
- San Francisco, CA
- Medicare CCN
- 054144
- Received
- $73,663,874 in 2,931 records, 2022 ($3,838,229 general, $69,825,645 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 435 | $3,838,229 |
| 2022 | Research payment | 2,496 | $69,825,645 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 2,496 | $69,825,645 |
| Grant | 89 | $1,733,392 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 90 | $543,019 |
| Royalty or License | 28 | $503,291 |
| Space rental or facility fees (teaching hospital only) | 121 | $372,754 |
| Education | 90 | $345,483 |
| Consulting Fee | 9 | $289,073 |
| Charitable Contribution | 6 | $49,500 |
| Debt forgiveness | 1 | $1,365 |
| Long term medical supply or device loan | 1 | $350 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,617,491 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Enhancing sensitivity to immune checkpoint and androgen receptor blockade in small cell neuroendocrine and intermediate | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $989,964 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Immunogenic Priming with PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer A Phase 1b Study of 177Lu-PSMA-61 | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $945,870 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A pilot study of pembrolizumab and liver-directed therapy for patients well-differentiated neuroendocrine tumors and sym | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $414,856 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Metastatic Colorectal Cancer | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $356,562 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Study of Neoadjuvant Pembrolizumab-Based Combination Therapy in Patients with Locally Advanced or Metastatic | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $345,471 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Pilot Study of Pembrolizumab , an anti-PD programmed cell death-1 Antibody, in Combination with Carboplatin in Breast | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $304,815 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase II Study of Checkpoint Inhibition with Anti-PD-1 Alone or Anti-PD-1 in Combination with Intratumoral Poly-ICLC The | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $261,903 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A phase II study of stereotactic radiosurgery in conjunction with the PD-1 inhibitor , pembrolizumab for the treatment o | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $219,351 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $199,007 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Testing the ability of MK-3475 to alter the tumor immune microenvironment of high grade, high risk DCIS | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $157,111 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 2 open label study of pembrolizumab in patients with metastatic castrate resistant prostate cancer mCRPC with or w | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $95,370 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $89,012 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab MK-34 | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $86,803 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $68,773 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Che | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $64,129 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $59,188 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $58,645 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $53,241 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01 Master Study A Phase 2 Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $51,713 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $48,474 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,1b, Open label Clinical Study of Intratumoral,Intralesional Administration of V938 in Combination with Pembrol | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $39,096 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1 Open-Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for P | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $33,188 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $33,182 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | Randomized, Placebo-Controlled Trial to Evaluate the Safety of Letermovir PrevymisTM in Adults with Human Immunodeficien | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $31,168 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $29,047 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671,V941 as a Monotherapy and in | 2022 |
| 2022-12-31 | AstraZeneca UK Limited | $28,009 | Research payment | In-kind items and services | A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants wit | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $24,623 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $20,939 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $18,452 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $17,904 | Research payment | In-kind items and services | Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. | 2022 | |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $14,470 | Research payment | In-kind items and services | Biograph mCT X-4R Device, MI - Nuclear Medicine (incl. PETNET & MIBR) | Evaluation of myocardial uptake image quality in wholebody PET scans with OncoFreeze AI | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $13,985 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $13,562 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $13,398 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | A Phase III, Randomised, Controlled, Multi-centre Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $13,353 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $12,744 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Che | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $12,716 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Flourouracil in Subjects wi | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $12,501 | Research payment | In-kind items and services | LOKELMA Drug, Cardiovascular and Metabolism | NEUTRALIZE - Lokelma Metabolic Acidosis Study A double-blind randomized placebo-controlled parallel design multicenter p | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $10,636 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 1b,2 study of immune and targeted combination therapies in participants with RCC | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $10,636 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants With RCC KEYMAKER-U03 Substudy 03B | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $10,339 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $7,786 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial of Pembrolizumab MK-3475 in Subjects with Advanced,Unresectable or Metastatic Urothelial Cance | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $7,545 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2022 |
| 2022-12-31 | Boston Scientific Corporation | $6,766 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $6,655 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in Fi | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $6,097 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $6,070 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Two-Arm, Open-label, Randomized Phase III Study of Pembrolizumab MK-3475 monotherapy versus standard chemotherapy in P | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,873 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase 2b open-label, single-arm trial to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,860 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $5,833 | Research payment | In-kind items and services | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF DATO-DXD VERSUS INVESTIGATORS CHOICE OF CHEMOTHERAPY IN PARTICIPANTS WITH INO | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,641 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,570 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial of Pembrolizumab MK-3475 in Subjects with Advanced,Unresectable or Metastatic Urothelial Cance | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $5,250 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,862 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,678 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $4,578 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $4,578 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,366 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Flourouracil in Subjects wi | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $4,344 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $4,344 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $4,249 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,246 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in Fi | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,209 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy f | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,195 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,193 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab MK-3475 in Locally Advanced,Metastatic Ren | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,994 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,967 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,955 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally A | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,850 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $3,638 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,633 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,582 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $3,016 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,986 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial of Pembrolizumab MK-3475 in Subjects with Advanced,Unresectable or Metastatic Urothelial Cance | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,799 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma KEYNOTE-224 | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,641 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,632 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab MK-3475 in Locally Advanced,Metastatic Ren | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,523 | Research payment | In-kind items and services | ZINPLAVA Biological, INFECTIOUS DISEASE | Protocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Phar | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,503 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma KEYNOTE-224 | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,408 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A phase II trial of MK3475 in Merkel Cell Carcinoma MCC | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,263 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,245 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,179 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,047 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,032 | Research payment | In-kind items and services | ZINPLAVA Biological, INFECTIOUS DISEASE | Protocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Phar | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,022 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,923 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,836 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,374 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,308 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,229 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $921 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $903 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Two-Arm, Open-label, Randomized Phase III Study of Pembrolizumab MK-3475 monotherapy versus standard chemotherapy in P | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $872 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $872 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $829 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $829 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $829 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $786 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Che | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $778 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy f | 2022 |
| 2022-12-31 | ABBVIE INC. | $773 | Research payment | In-kind items and services | RST001 Phase I II Trial for Advanced Retinitis Pigmentosa | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $713 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $661 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinomas and Melanom | 2022 |
| 2022-12-31 | Abbott Laboratories | $644 | Research payment | In-kind items and services | Device, Core Diagnostics | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $624 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $554 | Research payment | In-kind items and services | A Modular Phase I IIa Open label Multi centre Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $544 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $544 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $472 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $472 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $472 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $472 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $442 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $442 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $430 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase 2b open-label, single-arm trial to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $395 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $387 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $347 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $347 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $340 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $300 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $277 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $275 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $275 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $275 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | AstraZeneca UK Limited | $270 | Research payment | In-kind items and services | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $251 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $236 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $236 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $236 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $221 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $221 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectab | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $161 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $161 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $157 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $125 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $112 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $112 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $112 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $111 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $90 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $70 | Research payment | In-kind items and services | Biological, VACCINE | A Study to Evaluate the Efficacy of GARDASILTM in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related External Ge | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $66 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | ABBVIE INC. | $63 | Research payment | In-kind items and services | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $62 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial of Pembrolizumab MK-3475 as Monotherapy for Metastatic Triple Negative Breast Cancer mTNBC K | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $57 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $57 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | Abbott Laboratories | $33 | Research payment | In-kind items and services | Device, Core Diagnostics | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $17 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 1b,2 study of immune and targeted combination therapies in participants with RCC | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01Substudy 1 A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combi | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants With RCC KEYMAKER-U03 Substudy 03B | 2022 |
| 2022-12-30 | Merck Sharp & Dohme LLC | $60,920 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv | 2022 |
| 2022-12-30 | Janssen Research & Development, LLC | $43,932 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2022 |
| 2022-12-30 | Janssen Research & Development, LLC | $14,659 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2022 | |
| 2022-12-29 | PUMA BIOTECHNOLOGY, INC. | $19,686 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEP | 2022 |
| 2022-12-29 | PFIZER INC. | $15,400 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2022 |
| 2022-12-29 | Abbott Laboratories | $4,174 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ARCHITECT Device, Core Diagnostics | 2022 | |
| 2022-12-28 | BioMarin Pharmaceutical Inc. | $452,776 | Research payment | Cash or cash equivalent | Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients | 2022 | |
| 2022-12-28 | United Therapeutics Corporation | $18,123 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2022 |
| 2022-12-28 | United Therapeutics Corporation | $15,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-12-28 | Roche TCRC, Inc. | $2,064 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2022 |
| 2022-12-28 | Roche TCRC, Inc. | $560 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2022 |
| 2022-12-27 | Genentech, Inc. | $116,708 | Research payment | Cash or cash equivalent | Drug | 2022 | |
| 2022-12-27 | Genentech, Inc. | $23,130 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ASSESSING DISEASE ACTIVITY IN MINORITY PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS USING OCRELIZUMAB | 2022 |
| 2022-12-27 | Janssen Research & Development, LLC | $19,606 | Research payment | Cash or cash equivalent | TREMFYA Drug, Immunology | Immunogenetic Profiling Of Guselkumab For The Treatment Of Plaque And Guttate Psoriasis | 2022 |
| 2022-12-27 | Haemonetics Corporation | $19,150 | Research payment | Cash or cash equivalent | TEG6S HEMOSTASIS SYSTEM Device, DEVICES | AN OBSERVATIONAL TRIAL TO ASSESS THE PERFORMANCE OF THE TEG 6S DIAGNOSTIC SYSTEM WITH THE CITRATED K KH RTH FFH CARTR | 2022 |
| 2022-12-27 | Roche Products Limited | $7,172 | Research payment | Cash or cash equivalent | Esbriet Biological, Immunology | PH III OLE TRIAL TO EVALUATE LONG TERM SAFETY AND EFFICACY OF PRM 151 IN PATIENTS WITH IPF | 2022 |
| 2022-12-26 | Janssen Research & Development, LLC | $48,109 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Multiarm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2022 |
| 2022-12-23 | Aadi Bioscience, Inc. | $22,605 | Research payment | Cash or cash equivalent | ABI-009 | A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid T | 2022 |
| 2022-12-22 | Genentech, Inc. | $240,834 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | IMPACT | 2022 |
| 2022-12-22 | Ultragenyx Pharmaceutical Inc. | $21,492 | Research payment | Cash or cash equivalent | Crysvita Drug, XLH Metabolic Bone Disorder | UX023-CL401 | 2022 |
| 2022-12-22 | Janssen Research & Development, LLC | $18,016 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2022 | |
| 2022-12-22 | ALBIREO PHARMA, INC. | $16,892 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro | 2022 |
| 2022-12-22 | AstraZeneca Pharmaceuticals LP | $4,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ANDEXXA Biological, Rare Disease | 2022 | |
| 2022-12-22 | Bio-Rad Laboratories, Inc. | $2,739 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Liquichek Device, Controls | 2022 | |
| 2022-12-22 | SEAGEN INC. | $2,314 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous | 2022 |
| 2022-12-22 | SEAGEN INC. | $2,186 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous | 2022 |
| 2022-12-22 | SEAGEN INC. | $2,186 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous | 2022 |
| 2022-12-22 | SEAGEN INC. | $2,186 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous | 2022 |
| 2022-12-22 | SEAGEN INC. | $2,186 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous | 2022 |
| 2022-12-22 | SEAGEN INC. | $2,186 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous | 2022 |
| 2022-12-22 | SEAGEN INC. | $2,186 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous | 2022 |
| 2022-12-22 | SEAGEN INC. | $2,186 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous | 2022 |
| 2022-12-22 | Bio-Rad Laboratories, Inc. | $330 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Liquichek Device, Controls | 2022 | |
| 2022-12-21 | Neurocrine BioSciences, Inc. | $11,037 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in | 2022 | |
| 2022-12-21 | Exelixis Inc. | $10,000 | Royalty or License | Cash or cash equivalent | 2022 | ||
| 2022-12-21 | Kite Pharma, Inc. | $9,064 | Research payment | Cash or cash equivalent | A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects with Relapsed/Refractory | 2022 | |
| 2022-12-21 | BioMarin Pharmaceutical Inc. | $6,322 | Research payment | Cash or cash equivalent | An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | 2022 | |
| 2022-12-21 | Sunovion Pharmaceuticals Inc. | $4,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-12-21 | PFIZER INC. | $3,861 | Research payment | Cash or cash equivalent | PHASE 3 OPENLABEL SINGLEARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF07055480 RECOMBINANT AAV26 HUMAN FACTOR VIII | 2022 | |
| 2022-12-21 | Olympus America Inc. | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | RICHARDS SINUSCOPE ADAPTOR FOR LIGHT CABLE Device, Ear, Nose, Throat | 2022 | |
| 2022-12-21 | Neurocrine BioSciences, Inc. | $3,234 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN | 2022 | |
| 2022-12-21 | Medical Device Business Services, Inc. | $3,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-12-21 | Gilead Sciences, Inc. | $1,557 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2022 |
| 2022-12-21 | Celgene Corporation | $1,477 | Research payment | Cash or cash equivalent | Phase IIIB Reblozyl Rollover - A Phase 3b, open label, single-arm rollover study to evaluate long term safety in subject | 2022 | |
| 2022-12-21 | Neurocrine BioSciences, Inc. | $1,388 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN | 2022 | |
| 2022-12-21 | Neurocrine BioSciences, Inc. | $664 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in | 2022 |
The latest 200 records of 2,931.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Francisco, CA | County San Francisco County, CA | State California |
|---|---|---|---|
| Population B01003 | 830,235 | 830,235 | 39,287,377 |
| Population, 2020 census P1 | 873,965 | 873,965 | 39,538,223 |
| Median age B01002 | 40.0 | 40.0 | 37.9 |
| Under 18 B01001 | 13.7% | 13.7% | 22.0% |
| 65 and over B01001 | 17.6% | 17.6% | 15.7% |
| Households B11001 | 363,970 | 363,970 | 13,548,091 |
| Foreign born B05002 | 34.0% | 34.0% | 27.0% |
| Median household income B19013 | $140,970 | $140,970 | $99,122 |
| Median family income B19113 | $171,141 | $171,141 | $113,346 |
| Per capita income B19301 | $92,289 | $92,289 | $49,513 |
| Poverty rate B17001 | 11.2% | 11.2% | 12.0% |
| Unemployment rate B23025 | 6.1% | 6.1% | 6.6% |
| Civilian labor force B23025 | 507,262 | 507,262 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.4 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 60.3% | 60.3% | 37.1% |
| Housing units B25001 | 414,602 | 414,602 | 14,644,735 |
| Owner-occupied B25003 | 38.2% | 38.2% | 55.9% |
| Renters B25003 | 61.8% | 61.8% | 44.1% |
| Median home value B25077 | $1,394,500 | $1,394,500 | $734,700 |
| Median gross rent B25064 | $2,476 | $2,476 | $2,036 |
| White, not Hispanic B03002 | 36.8% | 36.8% | 33.8% |
| Black B03002 | 4.7% | 4.7% | 5.2% |
| Hispanic or Latino B03002 | 16.2% | 16.2% | 40.2% |
| Asian B03002 | 34.9% | 34.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.
Comments